The Medicines Company ORION-10 Study for ASCVD
The Medicines Company (MDCO) announced positive topline results from the ORION-10 Phase 3 clinical trial in patients with atherosclerotic cardiovascular disease (ASCVD). The ORION-10 trial conducted with . . .
This content is for paid subscribers.
Today’s Highlights
September 26, 2019
